文献速递银屑病与炎症性皮肤病

银屑病一线生物制剂选择影响因素的前瞻性多中心队列研究

Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study.
PubMed 文献 · Br J Dermatol · 2017-07-26

该研究基于英国皮肤科医师协会生物干预注册登记数据(2012年1月至2015年12月),纳入3040例银屑病患者,采用多项逻辑回归分析影响一线生物制剂选择概率的因素,发现银屑病关节炎、体重、就业状态、注册国家和基线疾病严重程度影响选择,且处方行为随时间普遍变化。

要点

  • 银屑病关节炎、体重、就业状态、注册国家和基线疾病严重程度影响一线生物制剂选择。
  • 处方行为随时间发生普遍变化。
  • 结果为分层医学等未来处方行为变化的评估提供基线数据。

核心结论

  • 识别并量化了影响银屑病患者一线生物制剂选择的因素,包括银屑病关节炎、体重、就业状态、注册国家和基线疾病严重程度,且处方行为随时间普遍变化。

研究设计与样本

  • 前瞻性多中心队列研究,使用英国皮肤科医师协会生物干预注册登记2012年1月至2015年12月数据,主要分析纳入3040例银屑病患者,采用多项逻辑回归确定影响治疗选择概率的因素,并进行敏感性分析评估结果稳健性。

主要发现

  • 影响一线生物制剂选择的因素为:存在银屑病关节炎、患者体重、就业状态、注册国家、基线疾病严重程度。
  • 分析显示处方行为随时间发生普遍变化。
  • 结果对敏感性分析稳健。

临床怎么用

  • 研究结果有助于理解当前银屑病一线生物制剂处方实践的影响因素,并为评估分层医学等未来可能影响处方行为的变化提供基线数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Psoriasis Stratification to Optimise Relevant Therapy (PSORT) consortium has a collective aim to develop a prescribing algorithm to help stratify eligible patients with psoriasis to the most appropriate biological treatment. To facilitate the adoption of a stratified approach, it is necessary to first understand the factors driving the choice of first-line biological therapy. OBJECTIVES: To identify and quantify factors that influence the selection of the first-line biological therapy for people with psoriasis. METHODS: Multinomial logistic regression was used to determine the factors that influenced the probability of treatment selection, using data from the British Association of Dermatologists Biologic Interventions Register from January 2012 to December 2015. Sensitivity analyses were performed to assess the robustness of the findings to key assumptions. RESULTS: The main analysis was based on a dataset comprising 3040 people with psoriasis. The identified factors affecting first-line biological selection within the available therapies were: presence of psoriatic arthritis; patient weight; employment status; country of registration; and baseline disease severity. Importantly, the analysis showed a general shift in prescribing behaviour over time. These results were robust to sensitivity analysis. CONCLUSIONS: This study offers important insights into the factors influencing current prescribing practice for first-line biological therapies for people with psoriasis. It provides baseline data to inform the evaluation of future potential changes that may affect prescribing behaviour, such as stratified medicine.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Davison NJ, Warren RB, Mason KJ, et al. Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study. Br J Dermatol. 2017. PMID: 28386916. doi:10.1111/bjd.15551

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。